Alector, Inc. financial data

Symbol
ALEC on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
131 Oyster Point Blvd., Suite 600, South San Francisco, California
Fiscal year end
December 31
Former names
Alector LLC (to 9/16/2015)
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 353 % -39.5%
Debt-to-equity 299 % +13.4%
Return On Equity -103 % -51.9%
Return On Assets -25.7 % -38.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 97.3M shares +16.1%
Common Stock, Shares, Outstanding 97.3M shares +16.1%
Entity Public Float 384M USD -38.8%
Common Stock, Value, Issued 9K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 96.7M shares +15.8%
Weighted Average Number of Shares Outstanding, Diluted 96.7M shares +15.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 55.3M USD -45.8%
Research and Development Expense 186M USD -7.65%
General and Administrative Expense 57.1M USD -1.63%
Operating Income (Loss) -187M USD -19.4%
Income Tax Expense (Benefit) 3M USD -20%
Net Income (Loss) Attributable to Parent -161M USD -12.3%
Earnings Per Share, Basic -1.81 USD/shares -4.62%
Earnings Per Share, Diluted -1.81 USD/shares -4.62%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 47.5M USD -63.9%
Marketable Securities, Current 456M USD -8.57%
Assets, Current 520M USD -19.8%
Property, Plant and Equipment, Net 20M USD -17.9%
Operating Lease, Right-of-Use Asset 23.4M USD -11%
Other Assets, Noncurrent 6.12M USD -28.9%
Assets 571M USD -19.5%
Accounts Payable, Current 4.38M USD -6.26%
Employee-related Liabilities, Current 15.3M USD +19.9%
Accrued Liabilities, Current 23.1M USD +0.71%
Contract with Customer, Liability, Current 64M USD -6.69%
Liabilities, Current 148M USD +11.7%
Contract with Customer, Liability, Noncurrent 200M USD -18.7%
Operating Lease, Liability, Noncurrent 27.5M USD -16%
Other Liabilities, Noncurrent 1.23M USD +37.4%
Liabilities 420M USD -18%
Accumulated Other Comprehensive Income (Loss), Net of Tax -620K USD +55.3%
Retained Earnings (Accumulated Deficit) -785M USD -25.7%
Stockholders' Equity Attributable to Parent 151M USD -23.3%
Liabilities and Equity 571M USD -19.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -61.3M USD -26.4%
Net Cash Provided by (Used in) Financing Activities 71.1M USD +6490%
Net Cash Provided by (Used in) Investing Activities -11.8M USD -113%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 97.3M shares +16.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2M USD -105%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 49.1M USD -63.1%
Deferred Tax Assets, Valuation Allowance 205M USD +24.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 215M USD +22.2%
Operating Lease, Liability 38.9M USD -10.2%
Payments to Acquire Property, Plant, and Equipment 533K USD -48%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -160M USD -15.7%
Lessee, Operating Lease, Liability, to be Paid 48.5M USD -14%
Property, Plant and Equipment, Gross 49.9M USD +3.69%
Operating Lease, Liability, Current 8.61M USD +4.98%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.16M USD +4.91%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.86M USD +4.97%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.56M USD -26.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.48M USD +4.87%
Deferred Tax Assets, Operating Loss Carryforwards 12.4M USD -40.6%
Unrecognized Tax Benefits 20.2M USD +33.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.8M USD +4.82%
Additional Paid in Capital 936M USD +13.9%
Deferred Tax Assets, Net of Valuation Allowance 10.4M USD -10.5%
Share-based Payment Arrangement, Expense 41.8M USD -2.58%